SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Joe Wesley who wrote (9879)10/21/1997 10:09:00 AM
From: Arthur Radley  Read Replies (1) | Respond to of 32384
 
Thanks for the input A.A. Could you give us a recap of what they say or give us the location that we might find the info. Thanks again.



To: Joe Wesley who wrote (9879)10/21/1997 10:19:00 AM
From: Hippieslayer  Read Replies (2) | Respond to of 32384
 
Every analyst, so far, is praising the deal. This is like a review of a movie. The critics rave yet no one is seeing it. I think this is a case of wall st just doesn't understand biotechs that well ro that they just don't like LGNd. Case in point, CORR. Once they came out with the postive clinical on their drug, the stock took off. I know they are expecting fda approval, but is CORR anywhere near the company lgnd is?



To: Joe Wesley who wrote (9879)10/21/1997 2:47:00 PM
From: Andrew H  Read Replies (1) | Respond to of 32384
 
>>I'm not a lgnd expert however, I read BioCentury. They sent out an Extra this morning calling the Ligand-Lilly deal a Blockbuster.<<

Everyone seems to think its a blockbuster but the market. Nice that they sent out an extra. Can you provide us more detail on what was said.

As far as being an expert on LGND, don't worry. We have about 50 on the thread (:>)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News